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Panel: Research in context 31 
 32 
Evidence before this study 33 
Survival of shoulder replacements has often been reported in small case-series, with some follow-up 34 
extending beyond 20 years, however individual case-series are prone to bias and reporting has been highly 35 
heterogeneous. We searched MEDLINE and Embase for systematic reviews and meta-analyses of shoulder 36 
replacement series that were published in English. Of the 37 systematic reviews we identified, no articles 37 
reported combined survival estimates or patient reported outcome measures with more than 10 years follow-38 
up. A previous analysis of the UK Hospital Episode Statistics (HES) dataset, published in 2019, combined 39 
all types of shoulder implants and found overall survival to be 90·0% (95% CI 89·6% to 90·3%) at 10 years. 40 
No study to date has attempted to provide pooled survival estimates and pooled patient reported outcomes 41 
for shoulder replacements more than 10 years after surgery.   42 
Added value of this study 43 
To our knowledge, we provide the first pooled survival estimate, drawn from multiple sources, for shoulder 44 
replacements at 10 years. We have also shown that shoulder replacements have a sustained positive impact 45 
on patients’ lives to 10 years after surgery. Our findings showed that approximately 92% of total shoulder 46 
replacements, 91% of shoulder humeral hemiarthroplasties and 94% of reverse total shoulder replacements 47 
last for 10 years.  48 
Implications of all the available evidence 49 
Our findings provide valuable and overdue information for patients and clinicians considering shoulder 50 
replacement surgery. It is the first study to provide a simple and generalizable answer to two very important 51 
questions: “How long does a shoulder replacement last?” and “Will my shoulder be better in the long-term 52 
after surgery?” The data will also be useful for those commissioning healthcare services. 53 





Shoulder replacement is an increasingly common treatment for end-stage degenerative shoulder conditions.  57 
Some shoulder replacements will fail and further operations may be required. It is important for patients 58 
and clinicians to know how long shoulder replacements last and how effectively they improve pain and 59 
function. This study aims to determine the longevity and long-term efficacy of shoulder replacements.  60 
Methods 61 
In this systematic review and meta-analysis, we searched MEDLINE and Embase for articles reporting 10-62 
year or greater survival of Total Shoulder Replacements (TSR), Humeral Hemiarthroplasties (HA) and 63 
Reverse Total Shoulder Replacements (RTSR). Survival, implant and Patient Reported Outcome Measures 64 
(PROMs) data were extracted. National joint replacement registries were reviewed and analysed separately.  65 
We weighted each series and calculated a pooled survival estimate at 10, 15 and 20 years. For PROMs we 66 
pooled the Standardised Mean Difference (SMD) at 10 years.  67 
Findings 68 
We identified 10 series reporting all-cause survival of 529 TSRs and 420 HA, no series for RTSR met our 69 
inclusion criteria. The estimated 10-year survival for TSR was 95·6% (95% CI 93·6, 97·6) and HA 90·4% 70 
(95% CI 87·0, 94·0). A single registry contributed 7941 TSRs, 3495 HAs and 8049 RTSRs. The pooled 71 
registry 10-year survival for TSR was 92·0% (95% CI 91·0, 93·0), HA 90·5% (95% CI 81·8, 95·1) and 72 
RTSR 94·4% (95% CI 93·1, 95·7) for osteoarthritis and 93·6% (95% CI 91·0, 95·4) for rotator cuff 73 
arthropathy. Pooled 10-year PROMs revealed a substantial improvement from baseline scores (SMD 2·13 74 
95% CI 1·93, 2·34).         75 
Interpretation  76 
Over 90% of shoulder replacements last more than 10 years and patient reported benefits are sustained. 77 
This long overdue information will be of use to patients and health-care providers.  78 
Funding 79 
The National Institute for Health Research, the National Joint Registry for England, Wales, Northern 80 
Ireland, and Isle of Man, and the Royal College of Surgeons of England.  81 
4 
 
Introduction  82 
Patients with severe pain and disability from degenerative shoulder conditions want to know whether they 83 
will benefit from shoulder replacement surgery, which type of replacement may be best and what they can 84 
expect in the long-term following surgery.1 A review of seven national arthroplasty registers in 2017 85 
suggested there has been a secular increase in the number of shoulder replacements performed for patients 86 
with both osteoarthritis and rotator cuff tear arthropathy. Overall the annual incidence rate has increased 87 
2.8 fold in the last decade, but significant variation exists between countries.2 There is a paucity of high 88 
quality outcome data to aid joint decision making by patients and clinicians, and to assist both 89 
commissioners and providers in understanding the utility and likely revision burden associated with 90 
undertaking these procedures.  91 
Available randomised controlled trials (RCTs) are particularly limited, by size and design, in their ability 92 
to evaluate the longer-term outcomes and risks of primary shoulder arthroplasty, in particular the 93 
requirement for revision surgery.3 To better understand the long-term benefits and risks of shoulder 94 
replacement surgery for these patients, a formal appraisal and synthesis of the more frequently available 95 
non-randomised study data is needed. 96 
Ideally, clinicians and surgeons should be able to provide patients with contemporary condition-, age- and 97 
implant-specific outcome data for any proposed procedure and available alternatives. While implant 98 
manufacturers do facilitate the collection of implant-level data in order to gain relevant benchmark 99 
accreditation,4 detailed and reliable data are not yet available for shoulders. Until such granular brand-level 100 
information is available, clinicians and patients need accurate information on classes of available implants. 101 
Hip and knee replacement have shown that although there is variation between brands, classes of implants 102 
behave in broadly similar fashion.5,6  The three main constructs or classes available and referred to in this 103 
study are conventional total shoulder replacement (TSR), humeral hemiarthroplasty (HA), and reverse total 104 
shoulder replacement (RTSR). There is likely to be heterogeneity between indications for surgery, 105 
mechanisms of failure and overall revision rates between these different constructs.7  106 
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In this study we sought to answer a simple but important question posed by all patients: How long does a 107 
shoulder replacement last? We aimed to provide the best quality pooled estimates of implant survival at a 108 
minimum 10 years’ follow-up. The decision to revise a poorly performing shoulder replacement is 109 
multifactorial that may be sensitive to both patient and surgeon preferences. Therefore, we also aimed to 110 
make a pooled estimate of the likely patient reported outcome at long-term follow-up, in essence to answer 111 
the question: Will my shoulder be better 10 years after surgery? 112 
  113 
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Methods  114 
Search strategy and selection criteria 115 
We conducted a systematic review and meta-analysis assessing the survival of shoulder replacements in 116 
case-series and national joint registries following a predefined protocol registered with PROSPERO 117 
(CRD42019140221) and complying with PRISMA guidelines.8   118 
A search strategy using keywords and MeSH terms relating to shoulder replacement and survival (appendix 119 
1) was used in the databases MEDLINE and Embase accessed through OVID Silver Platter. The databases 120 
were searched from their commencement to 24th September 2019. The strategy development was guided 121 
by previously published search strategies exploring the survival of hip and knee replacements.9,10 Manual 122 
screening of the bibliographies of the full-text articles and systematic reviews was also undertaken. 123 
Studies were included if they assessed patients who had undergone any type of shoulder replacement (a 124 
total shoulder replacement (TSR), humeral hemiarthroplasty (HA) or reverse total shoulder replacement 125 
(RTSR)). Humeral components (stemmed, stemless or resurfacing) were all considered as TSR or HA 126 
dependent on whether the glenoid (shoulder socket) was replaced or not and not sub-classified. The 127 
indication (reason) for surgery had to be predominantly osteoarthritis (OA) or rotator cuff arthropathy 128 
(RTCA). For inclusion, the case-series or published registry report had to report the survival of a specific 129 
brand of implant with a mean or median follow-up of greater than 10 years. It is widely accepted that 130 
survival of hip arthroplasties varies by the brand of implant.5 Although this has not specifically been 131 
assessed in shoulder replacements, the technique of treating each brand as its own series was utilised as 132 
variation in survival by brand exists in hip and knee replacements, therefore the assumption would seem 133 
sensible for shoulder replacements as well. Weighting of implants in the meta-analysis would therefore 134 
provide the most robust survival estimates. This allows us to treat each series as an individual study and 135 
weight the meta-analysis of survival results according to the standard error of each series. Aggregate data 136 
from multiple implant brands would not allow this granularity and thus hide the potential variability in 137 
performance between implant brands. A cut-off of minimum mean or median follow-up of 10 years was 138 
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chosen as the subject of interest of this study was “long-term” survival, where there is a current paucity of 139 
information. We accept this definition may vary subjectively but 10 years allowed inclusion of sufficient 140 
studies to make analyses robust and represents a time period that is relatable to patients and clinicians. 141 
 Studies were excluded if they reported the outcome of revision surgery, as this is often more complex 142 
surgery and carries different survivorship. Conference abstracts were excluded due to the limited data 143 
available from these reports. Systematic reviews were assessed for their citations but did not include their 144 
pooled data to avoid duplication.  145 
The reports from all available national joint registers that collect and publish the individual implant-specific 146 
survivorship for shoulder replacements with at least 10-years of follow-up were assessed. Reports were 147 
identified through the systematic search if published or accessed through their websites.  148 
Article screening and data extraction  149 
Screening was undertaken in a stepwise manner using the web application Rayyan.11 Journal article titles 150 
and abstracts were screened by two reviewers (JTE and HM) with arbitration of conflict undertaken by JPE. 151 
Full-text review and data extraction were undertaken by two reviewers independently (JPE and JTE). Data 152 
extracted were: publication date, baseline population demographics, number of patients (n), surgical 153 
indication proportion (% OA and/or % RCTA), follow-up duration (>10 years), implant name and construct 154 
type (TSA, HA or RTSA), loss to follow-up, survival estimates (including CIs) and all available Patient 155 
Reported Outcome Measure (PROM) (e.g. Visual Analogue Scales (VAS), Constant score, Disabilities of 156 
the Arm, Shoulder and Hand (DASH)), data (outcome measure used baseline mean score (SD), follow-up 157 
duration in 5 year increments, follow-up mean score (SD)). Data were not extracted from figures (e.g. 158 
Kaplan Meier plots) to avoid potential transcription inaccuracy. Discrepancy in extracted data was 159 
discussed by the authors, following which there were no cases of disagreement.  160 
Statistical Analysis 161 
For the assessment of the published case-series our primary exposure was the shoulder replacement implant 162 
and our primary outcome was all-cause revision, of any part of this construct, as guided by our patient 163 
8 
 
group.12 Statistical analysis was performed with Stata 15 (Stata Statistical Software: Release 15. College 164 
Station, TX: StataCorp LLC). Survival estimates, assuming that survivorship approximated revision risk, 165 
were pooled by meta-analysis. Each series was weighted according to its standard error (calculated from 166 
published confidence intervals). The effect size (Standardised Mean Difference (SMD)) of the primary 167 
PROMs reported in each study was pooled with meta-analysis with weighting according to sample size and 168 
analysed using a random effects model as a more conservative estimate of treatment effect. Effect size was 169 
considered small if it was less than ≥0·2, moderate if ≥0·5 and large if ≥0·8.13  170 
Quality assessment 171 
Study quality was assessed using the non-summative four-point system (consecutive cases, multi-centre, 172 
under 20% loss to follow-up and use of multivariable analysis) developed by Wylde et al.14 This was 173 
selected in preference to the summative MINORS score due to the high loss to follow-up in joint 174 
replacement case-series and because some of the scoring criteria in MINORS were not relevant to joint 175 
replacement.  176 
 177 
Role of the funding source 178 
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or 179 
writing of the report. All authors had access to the raw data. The corresponding author had full access to 180 
all of the data and the final responsibility to submit for publication   181 
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Results  182 
The search of published case-series produced 1,376 articles. Of these, 449 duplicates were removed, leaving 183 
927 articles for screening (figure 1). After screening, 36 full-text articles were reviewed. Additional citation 184 
searches through previously published systematic review references yielded four further full-text reviews, 185 
none of which met the inclusion criteria. Following review of full-text articles, nine articles reporting 10 186 
individual implant specific series were included in the survival analysis, six articles that reported both 187 
survival analysis and PROMs were included in the PROMs analysis. A summary of study level 188 
characteristics is provided in Table 1. The proportion of OA as the primary surgical indication was 59% for 189 
TSR and 48% for HA. The reporting of indication was variable and was interpretable in only seven articles.   190 
Quality assessment revealed that six (60%) of the 10 series were consecutive, two (20%) were multicenter, 191 
nine (90%) had >80% follow-up (with mean loss to follow up of 8.4%, ranging from 0% to 23.7%),and 192 
none undertook multivariable analysis. These proportions are in keeping with the fact that the quality of 193 
published case-series is low.  194 
Case-series 195 
Six unique series, published between 1998 – 2015, reported survival of 529 total shoulder replacements 196 
(TSR) at 13 time points with follow-up ranging from 10 to 21 years (Appendix 2).15–21 Four reported 197 
survival at exactly 10 years (466 TSRs), three reported survival at 15 years (427 TSRs) and one reported 198 
survival at 20 years (19 TSRs). Pooled survival from those studies reporting at exactly 10 years was 95·6% 199 
(95% CI 93·6, 97·6) at 15 years 88·5% (95% CI 83·4, 94·1) and at 20 years 83·2% (95% CI 70·5, 97·8) 200 
(figure 2). When studies reported survival estimates at between 10 and 15 years, these results were rounded 201 
down to 10 years as a sensitivity analysis. This resulted in a pooled survival of six series (529 TSRs) of 202 
90·0% (95% CI 88·3, 91·7) (figure 3).  203 
Four unique series, published between 1998 – 2017, reported survival of 364 shoulder humeral 204 
hemiarthroplasties (HAs) at 10 time points with follow-up ranging from 10 to 21 years (Appendix 2).16,18,21–205 
23 Three reported survival at exactly 10 years (327 HAs), two at 15 years (151 HAs) and one at 20 years 206 
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(56 HAs). Pooled survival at exactly 10 years was 90·4% (95% CI 87·0, 94·0), at 15 years 90·6% (95% CI 207 
84·1, 97·1), and at 20 years 75·6% (95% CI 65·9, 86·5) (figure 2). Rounding down of reported survival 208 
from those series closest to >10 but <15 years resulted in a pooled survival of four series (364 HAs) of 209 
92·5% (95% CI 89·6, 95·3) (figure 3).  210 
No unique single implant series with a mean follow-up of at least 10 years were found for reverse total 211 
shoulder replacements (RTSA).   212 
Registry data 213 
The reports of implant-level data at 10 years were only available from a single registry, the Australian 214 
Orthopaedic Association National Joint Replacement Registry (AOANJRR) 2019 annual report.24 This 215 
report yielded 10-year survival of eight series of TSRs (7,941 arthroplasties), eight series of HAs (3,495 216 
arthroplasties) and five series of RTSRs (8,049 arthroplasties). Pooled survival estimates from registry data 217 
for TSRs at 10 years were 92·0% (95% CI 91·0, 93·0); for HAs 90.5% (95% 81·8, 95·1) and for RTSR 218 
were 94·4% (95% CI 93·1, 95·7) for a primary diagnosis of OA, and 93·6% (95% CI 91·0, 95·4) for a 219 
diagnosis of RTCA (single implant reported) (figure 4).  220 
Patient Reported Outcome Measures 221 
Of the 14 studies reporting survival analysis, six reported the implant level PROMs of 617 shoulder 222 
replacements for inclusion in the PROMs meta-analysis; this included two studies not included in the 223 
survival meta-analysis, excluded as they did not report confidence intervals.17,19,20,23,25,26 Four studies 224 
reported PROMs on TSR, one on RTSR and one on HA. All reported the outcome of shoulder-specific 225 
PROMs, without the addition of generic quality of life measures. Five studies reported the Constant score, 226 
one the simple shoulder test (SST) and one a four-point linear pain scale previously described by Neer.27 227 
Pooled PROMs data showed a large effect of improved outcome from baseline (SMD 2·13 95% CI 1·93, 228 
2·34) (figure 5). Subgroup analysis of PROMs exclusively from TSRs reduced the effect size marginally 229 
(SMD 2·02 95% CI 1·86, 2·19). Implant-level 10-year PROMs were not published in any registry reports. 230 
The New Zealand registry report 10-year PROMs, which were categorised by construct only (TSR, HA, 231 
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RTSR, Partial resurfacing of head). Although no baseline PROMs are available for comparison, at 10-years 232 
the Oxford Shoulder Score (OSS) mean for all implants was 39.1/48 (95% CI 38.4, 39.8), for TSA (n=335) 233 
41.0/48 (40.0, 42.0), HA (n=104) 39.4/48 (37.7, 41.1), RTSR (n=104) 39.4 (37.7, 41.1).  234 
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Discussion  235 
We found that 90% of shoulder replacements last for at least 10 years and that patients can expect a large 236 
and sustained improvement in their patient reported outcome measures.    237 
The methodology used is one that has been previously applied successfully to hip and knee replacement,9,10 238 
with the production of simple and generalisable results. The application of this process to shoulder 239 
replacement proved more complex due to sparsity and heterogeneity of data and highlights why the study 240 
question has not previously been answered. However, despite these limitations, the data from both registries 241 
and case-series independently estimate the same results. This is encouraging and suggests that these case-242 
series are not subject to selection and publication bias. 243 
The methods applied in this study use an individual estimate for each implant series, which is then 244 
synthesised to provide single pooled construct estimate weighted according to the standard error. The 245 
implant has been shown to be fundamental to the survival outcome of hip and knee replacement and is 246 
likely to be just as important in shoulder replacement and each individual series should be considered as a 247 
different patient cohort.5 We have used the individual estimates for each implant to synthesise a single 248 
pooled estimate, weighting the estimates according to standard error. This type of analysis, deriving an 249 
overall estimate according to how frequently each implant has been used, is unique to our study. This 250 
analysis is dependent upon case-series, and registries’ reporting of implant level data, as the only method 251 
where the patterns of implant failure can be accounted for. . 252 
Implant survival at more than 10 years was greater than 90% for both TSR and HA in the case-series data, 253 
and also in the Australian registry data. This finding is concordant with the limited number of extended 254 
survival reports using multi-implant cohorts, including the assessment of Hospital Episode Statistics (HES) 255 
data in England 28 of 90% (95%CI 89·6 - 90·3) in a combined arthroplasty cohort, and Mayo clinic registry 256 
data 29,30 of 90·2% (95% CI 88·7, 91·7) for TSR and 90·0% (95% CI 88·0, 92·0) for HA. This study found 257 
very limited extended case-series 20-year data, all from the Mayo group, with survival for TSRs of 83·2% 258 
and HAs 75·6%, which are lower than the HES report of 87·8% (95% CI 87·2, 88·4) at 18 years but 259 
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comparable to the full Mayo Clinic registry of 81·4% (95% CI 78·4, 84·5) for TSR, but worse than the HA 260 
survival of 85·0% (95% CI 81·8, 88·4) at a 20 years, notably there is a younger age cohort in their HA 261 
case-series. It is notable that the demographic characteristics from the case-series and registry data are 262 
similar for the TSR group, and concordantly their survival rates are also comparable. For the HA group, the 263 
case-series data contain a more male dominated and younger population. All but one of the case-series 264 
report an average age of <60yrs, therefore the survival findings from case-series may lack generalisability. 265 
For RTSR, there was an absence of any implant level data from case-series at more than 10 years. This is 266 
concerning as it is currently utilized in over 50% of shoulder replacements in the UK, Norway, Australia   267 
and New Zealand. 24,31–33 It is surprising that this change in practice has occurred so rapidly with such 268 
paucity of long-term outcome evidence, particularly after the well documented problems with the 269 
widespread adoption of unproven technology in joint replacement.6 It is therefore reassuring that we have 270 
been able to assess survival of RTSR at 10 years using data synthesised from the Australian registry data 271 
which reveals a survival of 94·0% (95% CI 93·1, 95·7) for OA and 93·6% (95% CI 91·0, 95·4) for RTCA.  272 
Of the studies that reported survival of shoulder replacements at a mean of >10 years, five did not include 273 
confidence intervals and could not be added to the meta-analysis, six reported the composite survival of 274 
cohorts that included multiple different implants. Addition of these data would have resulted in the inclusion 275 
of 1,482 arthroplasties, increasing the analysis cohort by >150%. Failure of individual components of the 276 
construct (e.g. the glenoid or humeral component in isolation) was also reported in a large series that was 277 
excluded from the meta-analysis owing to the absence of an all-cause construct survival estimate.34 278 
Although component-failure data are of interest, we would regard this as best reported as a secondary 279 
endpoint, with the all-cause 1-Kaplan Meier estimate as the most appropriate method of reporting 280 
survivorship, which should always include the number of shoulder replacements at risk at the time of 281 
reporting.35  282 
As shoulder replacement registries may not provide long-term survival for some time to come, we remain 283 
somewhat reliant on case-series data. If these series are to reliably inform the surgical community of 284 
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implants at risk, they must be transparently reported according to current guidance on the reporting of 285 
healthcare data.36 As novel implants and techniques are developed, we will also continue to be reliant upon 286 
case-series to highlight potential improvements in survivorship and function.  287 
This study has identified that at over 10 years from the primary intervention a large improvement (SMD 288 
2·13) in PROMs scores was maintained. A linear transformation, making all scores interpretable from the 289 
Constant score scale, also demonstrates a mean change score of 40·4, which exceeds the minimal clinically 290 
reported difference (MCID) of 12·8 ± 2·5 points for TSR.37 The authors recognise the concern regarding 291 
the validity of the Constant score, and suggest that future studies report PROMs with proven validity and 292 
responsiveness. The New Zealand registry provided the only published comparator of construct-level, but 293 
not implant level, PROMs data. At 10 years this was limited to 674 replacements. Their high OSS at 10 294 
years (80% of total score) does suggest a sustained benefit of shoulder replacements. As the New Zealand 295 
registry does not provide baseline pre-operative scores, comparison of SMD could not be undertaken.  296 
We echo the calls for consensus in outcome choice to facilitate synthesis of data. Initiatives that promote 297 
the use of core outcome sets include the Core Outcome Measures in Effectiveness Trials (COMET), 298 
Outcome Measures in Rheumatology (OMERACT) and the International Consortium for Health Outcome 299 
Measurement (ICHOM).38–40 Furthermore, the inclusion of PROMs in registry data has the potential to 300 
dramatically improve the assessment of patient-focused outcomes. Currently, clear associations between 301 
survival of a shoulder implant and the patient-focused domains of pain, function and quality of life cannot 302 
be ascertained.  303 
There are limitations of this work. The data did not allow stratification or adjustment for patient factors that 304 
may have affected outcomes in the pooled analysis. The analysis could not account for differing thresholds 305 
for revision between surgeons. It is notable that many of the historic series are derived from single-surgeon 306 
series and therefore surgeon preferences may alter the resultant weighted synthesis of survivorship. We also 307 
recognise that emergent techniques and implants may demonstrate superior (or inferior) survivorship and 308 
function that is yet to be demonstrated with long-term follow-up. The impact of historic series that have 309 
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utilised implants subsequently recognised as having worse outcomes can affect a synthesis of long-term 310 
outcomes. The series from Levy et al 16 which included metal-backed glenoid components had a large 311 
weighting that reduced the overall survival estimate. Reporting early failure of certain implants is important 312 
and for the best available overall estimates should continue to be included. As not all failure results in 313 
revision, we reported patient-reported outcomes to better define the overall value of shoulder replacement. 314 
Our pooled registry results are drawn exclusively from the Australian register. As the available follow-up 315 
in other registries increases, a wealth of data will soon become available, and we would encourage implant 316 
level reporting by brand and product line. We also assumed that survival estimates are equivalent to risks 317 
for generating pooled estimates, and although the assumption that no censoring occurs (patients dying with 318 
a shoulder in situ) is violated, it provides a useful method of aggregation in the absence of individual patient 319 
data. The aggregated estimates of survival are however the largest possible sample and this is the largest 320 
report of this type and length of follow-up.  321 
The strengths of this study include an inclusive and comprehensive design and realistic interpretation of 322 
survivorship that accounts for all revisions and not a limited or biased subset, as well as a patient outcome 323 
focus. From a patient perspective, all revision surgery carries risk and therefore all-cause revision should 324 
be considered.  325 
Conclusion 326 
By pooling survival from case-series and registry data, we have been able to provide a reliable estimate of 327 
10-year survival rate of shoulder replacements.  We found that over 90% of shoulder replacements last for 328 
at least 10 years. Patients experienced sustained and marked benefit to 10 years. This information should 329 
be reassuring for patients, health professionals and commissioners of health services. 330 
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